Outcomes in RBC transfusion‐dependent patients with L ow‐/ I ntermediate‐1‐risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS ‐004 study

Autor:	Bruno Quesnel, Brigitte Schlegelberger, Ghulam J. Mufti, Tommy Fu, Pierre Fenaux, Lennart Nilsson, Guillermo Sanz, Dominik Selleslag, Consuelo del Cañizo, Bouchra Benettaib, Arnold Ganser, Peter A. W. te Boekhorst, Odile Beyne-Rauzy, Moshe Mittelman, Gudrun Göhring, David G. Bowen, Eva Hellström-Lindberg, Michael Lübbert, Petra Muus, Agnès Guerci-Bresler, Uwe Platzbecker, Aristoteles Giagounidis
Rok vydání:	2014
Předmět:	Subset Analysis medicine.medical_specialty business.industry Myelodysplastic syndromes Hematology General Medicine medicine.disease Placebo Gastroenterology Surgery Thalidomide International Prognostic Scoring System Internal medicine medicine business Adverse effect Survival analysis Lenalidomide medicine.drug
Zdroj:	European Journal of Haematology. 93:429-438
ISSN:	1600-0609 0902-4441
Popis:	ObjectiveA subset analysis of the randomised, phase 3, MDS-004 study to evaluate outcomes in patients with International Prognostic Scoring System (IPSS)-defined Low-/Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with isolated del(5q). MethodsPatients received lenalidomide 10mg/d (days 1-21; n=47) or 5mg/d (days 1-28; n=43) on 28-d cycles or placebo (n=45). From the placebo and lenalidomide 5mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or 10mg at 16wk, respectively. ResultsRates of red blood cell-transfusion independence (RBC-TI) 182d were higher in the lenalidomide 10mg (57.4%; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a22dd0c9b8dee23a973eb134afc2b45a https://doi.org/10.1111/ejh.12380 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.